Ranibizumab 2.3mg/0.23ml solution for injection vials
NHS hospitals in England used £53,950,945 of indicative cost of Ranibizumab 2.3mg/0.23ml solution for injection vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is down 1.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ranibizumab 2.3mg/0.23ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ranibizumab 2.3mg/0.23ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Norfolk & Norwich University Hpl Nhs Trt | £3,947,860 |
| Derby Teaching Hospitals Nhs Found Trust | £3,323,908 |
| Maidstone And Tunbridge Wells Nhs Trust | £3,310,821 |
| Wye Valley Nhs Trust | £2,412,058 |
| Gloucestershire Hpls Nhs Foundation Trst | £2,327,259 |
| University Hospitals Plymouth Nhs Trust | £2,251,358 |
| Frimley Health Nhs Foundation Trust | £2,160,278 |
| Nottingham University Hospitals Trust | £2,082,808 |
| James Paget Univ Hospitals Nhs Ft | £1,886,514 |
| Kingston Hospital Nhs Trust | £1,720,057 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.